Prospectus for Enzymatica’s rights issue is published
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, SINGAPORE, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. The prospectus for Enzymatica AB’s rights issue of around SEK 59 million has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen).The prospectus can be obtained from Enzymatica and Erik Penser Bank, and are available at Enzymatica’s web site (www.